Tesaro to Pursue PARP Inhibitor Indication in Overall Recurrent Ovarian Cancer Without Myriad CDx | GenomeWeb

NEW YORK (GenomeWeb) – Based on a Phase III trial that showed Tesaro's PARP inhibitor niraparib benefitted recurrent ovarian cancer patients regardless of their BRCA mutation status, the drugmaker has decided to pursue market approval of the drug in the overall patient population.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

Sponsored by
Agilent Technologies

This webinar will provide specific use cases from a molecular pathology lab demonstrating how an automated bioinformatics pipeline can improve somatic variant assessment and reporting.